From professional translators, enterprises, web pages and freely available translation repositories.
118 ανθρώπινη ερυθροποιητίνη και την ομάδα ελέγχου.
in the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls.
παρατηρήθηκε σε ασθενείς που έλαβαν ανασυνδυασµένη ανθρώπινη ερυθροποιητίνη.
there is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant ct